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Clinical outcomeAbstract Background: Despite the fact that colistin has a significant activity against MDR
gram-negative organisms, its toxicity limits its use. However, the limited therapeutic options due
to increasing antibiotic resistance have made re-evaluation of older antibiotics inevitable. In
contrast, lack of data to guide the usage of these drugs demands for studies on their safety and effi-
cacy. This studies the clinical outcomes and safety of colistin at a tertiary care centre in Mumbai.
Materials and methods: A prospective observational study was conducted at P.D. Hinduja
Hospital, Mumbai for a period of seven months. Diagnosis of infection was based on CDC guide-
lines and APACHE II score was used to assess the severity of illness. Clinical and microbiological
response to colistin was evaluated along with the incidence of nephrotoxicity (RIFLE criteria) and
neurotoxicity.
Results: Sixty-two patients (median age 56 years, with documented gram negative bacterial
infection and mean APACHE II score 22) received colistin. Clinically favourable response was seen
in 71% patients. However, the mortality among the study population was 27%. Univariate analysis
identified pneumonia and ICU admission as independent factors for adverse outcome. Deteriora-
tion of renal function was observed in 35.89% as per RIFLE criteria. 6 (9.6%) patients
demonstrated neurotoxicity.
68 K. Desai et al.Conclusion: Colistin is effective in treatment of gram negative infections and its use should be
reappraised. However since colistin is the last resort it is imperative to make its best use to ensure
that it remains as a safe and effective mode of treatment when need be.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colistin, a polymyxin class of antibiotic, was used for about
two decades after its discovery in 1950, but the reported
nephrotoxicity and neurotoxicity led to a gradual decrease in
its use by 1970s [1–3]. Now with the increase in antibiotic resis-
tance and the immediate threat of a decline in the discovery
and development of new antibiotics, treatment of serious gram
negative infections has almost reached the pre-antibiotic era
[4]. Virtually no drugs are available to effectively treat MDR
gram-negative pathogens. Thus restricted therapeutic options
have made the medical fraternity rekindle interest in colistin;
previously discarded due to toxicity and availability of safer
and less toxic antibiotics [5]. It has been reported that colistin
has significant activity against MDR gram negative pathogens,
but the safety and efficacy profile of colistin, to guide its usage
is not reported in the Indian population, with limited studies
across the globe. Hence, this study was performed to present
data regarding the clinical characteristics, and outcome (clini-
cal and microbiological) with emphasis on adverse events
(nephrotoxicity and neurotoxicity) of a group of patients with
resistant gram-negative infections being treated with colistin.
2. Materials and methods
2.1. Study site and design
The study was conducted at P.D. Hinduja National Hospital
and Medical Research Center (PDHNH and MRC), Mahim,
Mumbai. It is a tertiary care hospital, with 380 inpatient beds.
It was a single-centre, prospective observational study, carried
out from June 2010 to January 2011, approved by the Institu-
tion Review Board (IRB) of PDHNH and MRC.
2.2. Patient inclusion and exclusion criteria
Inclusion criteria: (a) patients more than 18 years of age admit-
ted to the ICU or wards of the hospital and (b) on intravenous
colistin for microbiologically documented gram negative infec-
tions for at least 72 h, were included.
Exclusion criteria: (a) pregnant and nursing women and (b)
patients infected with micro-organisms resistant to colistin
such as, Proteus spp., Serratia spp., Morganella spp. and, (c)
patients receiving less than 72 h of treatment with Colistin
were excluded.
2.3. Data collection
All patients prescribed colistin were identified prospectively
from the hospital pharmacy. A standard case report form
was used to capture demographic and hospital admission
details, reason for admission and co-morbidities. APACHEII [6] score was calculated at the time of ICU admission and
one day before starting colistin to assess the severity of illness.
All available culture sensitivity reports, laboratory data,
dosage and duration of colistin therapy, simultaneous co-
infections, use of other antibiotics and concomitant use of
nephrotoxic drugs were documented.
2.4. Definition of infections and outcome
2.4.1. Site of infection
Type of infection was assessed according to US Centers for
Disease Control and Prevention (CDC) criteria. Specifically,
diagnosis of pneumonia required chest radiographs with at
least one of the following: new or progressive and persistent
infiltrate, consolidation, cavitation, or pleural effusion. In
addition, patients must have had fever >38 C with no other
recognised cause, or abnormal white blood cell count [leucope-
nia (<4000 WBC/mm3) or leucocytosis (P12.000
WBC/mm3)], and at least two of the following: new onset of
purulent sputum or change in character of sputum, increased
respiratory secretions or increased suctioning requirements,
new onset or worsening of cough or dyspnoea or tachypnea,
rales or bronchial breath sounds, or worsening gas exchange
[7]. Bacteremia required growth of a recognised pathogen from
one or more blood specimen cultures [8]. Infections at other
body sites or fluids, such as urinary tract infections and surgi-
cal site infections were defined based on guidelines from CDC.2.4.2. Products administered
Each patient either received, Colomycin; Forest Laboratories,
UK or Xylistin; Cipla Pharmaceuticals, India, administered
intravenously at a dose of 2 million units three times a day,
in most patients with normal renal function. Patients with
pre-existing renal insufficiency received colistin dose corrected
for their creatinine clearance. Defined Daily Dose (DDD) was
calculated for the convenience of comparison of doses used in
different patients. No. of DDD=No. of items issued X
amount in each vial/WHO DDD measure. WHO DDD mea-
sure for parenteral use of colistin is 3 MU [9].
2.4.3. Microbiological testing
Identification of all causative microorganisms was performed
by classic microbiologic methods. Susceptibility testing was
performed using the Clinical and Laboratory Standards
Institute Guidelines (CLSI) 2010 for Pseudomonas and
Acinetobacter spp. [10]. EUCAST criteria were used for Enter-
obacteriaceae. Bacteria for which MIC to colistin was 2 mg/l
or less were considered susceptible while bacteria with MIC
4 mg/l or more were considered resistant. Susceptibility to col-
istin was tested with the use of 10 lg of colistin disc for Pseu-
domonas. Isolates were considered sensitive if the inhibition
zone was 11 mm or more.
Table 1 Demographic and clinical Characteristic for patients
enrolled in the studied.
Characteristic Values
(n= 62)
Age (years) (median, range) 56 (18–92)
Male gender [n (%)] 44 (71)
ICU admission [n (%)] 41 (66)
APACHE II score one day prior to staring colistin
(mean ± SD)
22 ± 8
Underlying condition (%)
None 21
Hypertension 12
Diabetes mellitus 04
HTN+DM 08
Respiratory 07
Malignancy 07
Cardiac 03
Multiple 37
Total hospital stay (mean ± SD) 35 ± 29
Day in hospital until 1st day of colistin
(mean ± SD)
11 ± 8.5
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2.5.1. Microbiological outcome
Bacteriological eradication was defined as, eradication of gram
negative isolates on follow up culture, wherever available. Pre-
sumed eradication was defined as no repeat culture was avail-
able and the patient had a favourable clinical response.
Presumed non eradication was defined as no repeat culture
was available and patient had an unfavourable clinical
response. Persistence was defined as continued isolation of
the gram negative isolate on follow up culture. Superinfection
was defined as isolation of a same or different gram-negative
organism from a different site while on colistin.
2.5.2. Clinical outcome
Favourable response was defined as complete or partial resolu-
tion of presenting signs and symptoms. Unfavourable response
was defined as persistence or worsening of presenting signs and
symptoms. Indeterminate response was defined as inability to
assess clinical response. Death was defined as death occurring
during colistin treatment [11].
2.5.3. Evaluation of response
All patients were followed up to record the clinical and micro-
biological outcome at the end of treatment. For nephrotoxicity
evaluation, the baseline creatinine and the highest creatinine
value during colistin therapy were noted and RIFLE (Risk,
Injury, Failure, Loss and End Stage Kidney Disease) criteria
were estimated. RIFLE criteria define three grades of severity
of AKI (Risk, Injury and Failure) based on changes to serum
creatinine and urine output and two clinical outcomes (Loss
and End-stage) [12]. In this study we used the creatinine crite-
ria to check for renal function deterioration. The case notes
were evaluated for any neurotoxic event independent of the
cause. The clinical criteria used in the evaluation included res-
olution of clinical signs and symptoms, including: Tempera-
ture less than 38 C, White cell range 4  109/L–12  109/L
and confirmation about resolution of signs and symptoms as
per the treating consultant.
2.5.4. Statistical analysis
All statistical tests were performed using Stata version 10.1.
For qualitative data Chi square test and Fischer’s exact test
were used for univariate analysis. Mean and standard devia-
tion were calculated for quantitative data. Wilcoxon’s rank-
sum test was used to compare each variable with outcome indi-
vidually. A p-value of <0.05 was deemed statistically signifi-
cant. Variables with p< 0.2 in the univariate analysis were
considered for inclusion in the multivariate analysis using the
multiple forward logistic regression method.
3. Results
3.1. Study population
(Table 1) In total 108 patients were screened from a period of
June 2010 to January 2011, of which 62 were included in study
(summarised in Fig. 1).
Pseudomonas aeruginosa (41.9%) and Acinetobacter spp.
(24.2%) were the most common causative organisms, followedby Klebsiella pneumoniae (16%). Colistin was most commonly
prescribed for pneumonia (27%) followed by other lower res-
piratory tract infection (18%) and UTI (18%), bacteremia
(16%) and surgical site infection (13%). 74% of all the isolates
were resistant to other antibiotics and patients received
monotherapy with colistin. The mean DDD of colistin in
patients with normal baseline creatinine was 16 (±8.65) and
11 (±9.5) in patients with high baseline creatinine. The
average no. of days of therapy with colistin was 11 ± 5.4 days.
3.2. Clinical and microbiological outcome
A clinically favourable response was seen in 44 (71%) out of 62
patients, clinical assessment was not possible in 1 and there
were 17 (27%) deaths while the patients were on colistin. Of
the 44 patients with a clinically favourable response 30 were
categorised as presumed eradication, 7 were documented erad-
ication, 5 with persistent infection and 2 were super infection.
Mean duration for mortality from starting colistin was
7 days; cause of death in 12 patients was septic shock with
multi-organ failure (MOF), sepsis in 3 patients, severe sepsis
in 1 and MOF with pneumonia in one patient.
Microbiological response was evaluated in 48 patients; 63%
had presumed eradication, 15% had eradication of gram neg-
ative isolates, 10% showed persistence and 12% had superin-
fection. 14 patients categorised as presumed non eradication
had died due to ongoing infection.
ICU admission and pneumonia were independent factors;
significant for adverse outcome in the univariate analysis
(Table 2). Male gender, ICU admissions, APACHE II score
1 day prior to starting colistin, pneumonia and number of
DDDs of colistin administered were controlled for in the
multivariate analysis. However, no factor was found to be sta-
tistically significant in the multivariate analysis (Table 3).
Figure 1 Patient accountability chart.
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Total 39 patients were evaluated for nephrotoxicity (17
patients were excluded due to death, 5 were excluded as they
were receiving renal replacement therapy prior to starting col-
istin and one was excluded as the patient was transferred to
another hospital). 25 patients had normal baseline creatinine
and 14 had a high baseline creatinine. Fig. 2 gives classification
of patients based on RIFLE criteria. Incidence of nephrotoxi-
city as per RIFLE criteria was found to be 35.89% and the
incidence of Acute Kidney Injury (AKI) and Acute Renal Fail-
ure was found to be 15.38%. No significant predictor of
nephrotoxicity was found in the univariate analysis (Table 4).Table 2 Univariate analysis of factors associated with adverse outc
Characteristic
Age (years) (mean ± SD)
Male gender [n (%)]
ICU admission [n (%)]
APACHE II score at ICU admission (mean ± SD)
APACHE II score 1 day prior to starting colistin (mean ± SD)
No. of Defined Daily Doses (mean ± SD)
Underlying disease [n (%)]
Hypertension
Diabetes mellitus
HTN+DM
Respiratory
Cardiac
Malignancy
Multiple
Others
Length of hospital stay (days) (mean ± SD)
Duration of hospitalisation until 1st day of colistin treatment (days) (mea
Responsible pathogen [n (%)]
Pseudomonas aeruginosa
Acinetobacter spp.
Klebsiella pneumoniae
Polymicrobial
Others
Condition treated [n (%)]
Bacteremia
Pneumonia
LRTI
UTI
SSI
Others3.4. Neurotoxicity
Six patients (9.6%) showed neurotoxicity in the form of focal
seizures not attributable to other identifiable cause.
4. Discussion
This study reveals prospective observational experience with
the use of colistin, a cationic polypeptide antibiotic of the poly-
myxin family that is rapidly bactericidal to Gram negative
bacteria.
The study enrolled total of 62 patients included in the anal-
ysis. A clinically favourable response was seen in 71% patients.
This is in keeping with previous studies that have confirmed
efficacy of colistin in the treatment of Gram-negative bacterial
infections between 45% and 88% [13–18].
A retrospective study performed on cohort of patients trea-
ted with colistin for microbiologically documented infections
in 258 patients has been reported [19]. In this study, a clinical
cure rate of 83.3% was observed in patients treated with col-
istin monotherapy or colistin combined with meropenem.
The presence of malignancy and infections other than pneumo-
nia were independent risk factors for failure to cure the infec-
tion. In another study, it was found that the severity of illness
(APACHE II score) was the only significant predictor ofome.
Favourable response
(n= 44)
Death
(n= 17)
P-
value
57 ± 20 55 ± 15 0.717
34 (77) 09 (52) 0.061
24 (54.55) 16 (94) 0.0035
19.33 ± 8.46 21 ± 8.35 0.376
20.58 ± 8.4 24.31 ± 7 0.074
15 ± 9.97 10 ± 5.4 0.06
5 (11.36) 2 (11.76) 0.964
3 (6.8) 0
4 (9.09) 0
2 (4.54) 2 (11.8) 0.308
1 (2.72) 1 (5.9) 0.483
3 (6.8) 1 (5.9) 1
16 (36.36) 7 (41.1) 0.728
1 (22.72) 0
39 ± 32.06 23 ± 14.9 0.019
n ± SD) 10 ± 7.5 15 ± 10.19 0.083
18 (40.9) 8 (47.2) 0.663
12 (27.27) 3 (17.6) 0.433
7 (15.9) 3 (17.6) 0.869
4 (9.09) 0
3 (6.8) 3 (17.6) 0.202
7 (15.9) 2 (11.6) 0.6824
9 (20.45) 8 (47.05) 0.037
9 (20.45) 2 (11.76) 0.428
9 (20.45) 2 (11.76) 0.428
7 (15.9) 0
3 (6.8) 2 (11.76) 0.612
010
No
 R
isk
In
ju
ry
Fa
ilu
re
 R
isk
20
19
5 4
1
6
3 1 0
N
o.
of
 P
at
ie
nt
s
RIFLE class
Nephrotoxicity
High Creat 
Normal Creat
Figure 2 Incidence of nephrotoxicity using RIFLE criteria.
Table 3 Multivariate analysis of risk factors associated with
adverse outcome OR, Odds Ratio; CI, Confidence Interval.
Risk factor OR (95% CI) P-value
Male gender 0.439 (0.10–1.85) 0.263
ICU admission 3.498 (0.13–89.29 0.449
Pneumonia 0.287 (0.06–1.35) 0.116
APACHE II score one
day prior to starting colistin
0.96 (0.87–1.05) 0.408
DDD 1.115 (0.99–1.24) 0.057
Clinical Outcomes and Safety of Colistin 71clinical response to colistin [20]. However, univariate analysis
in our study identified pneumonia and admission to the ICU
as independent risk factors for adverse outcome, and efficacy
of colistin did not differ against a particular organism. These
risk factors were not found to be significant on multivariate
analysis.
Nephrotoxicity is an important adverse effect of colistin
treatment and renal function should be closely monitored.
Deterioration of renal function could be a part of the ongoing
sepsis and multi-organ failure; hence patients with death as the
outcome were excluded from evaluation of nephrotoxicity.
Incidence of nephrotoxicity reported in literature is 9–56%
[21–24]. The occurrence of AKI and ARF was relatively lower
(15.38%) in this study compared to other studies. No factor
was found to be a significant predictor of nephrotoxicity in thisTable 4 Univariate analysis of risk factors in patients with and wit
Parameter Patients with n
(n= 14)
Age (years) (mean ± SD) 65 ± 18.46
DDD (mean ± SD) 17 ± 9.5
Duration of colistin therapy (days) (mean ± SD) 12 ± 6.45
APACHE II score 1 day prior to starting colistin
(mean ± SD)
20 ± 6.3
Co-administration of nephrotoxic drugs [n (%)] 11 (78)
Underlying disease [n (%)]
DM 2 (14.28)
HTN 1 (7.14)
DM+HTN 1 (7.14)
Respiratory 0
Cardiac 0
Cancer 1 (7.14)
Multiple 6 (42.85)
Others 0study, which could be due to the small sample size. None of the
patients showing AKI or ARF required initiation of
haemodialysis.
The incidence of neurotoxicity was found to be 9.6%. Of
the 6 patients, 2 were on combination treatment with car-
bapenems (doripenem and meropenem), which have a low inci-
dence of neurotoxicity. One patient had an underlying CNS
malignancy and one was admitted with diffuse axonal head
injury both of which can independently cause seizures. In stud-
ies by Cheng et al. and Holloway et al., 3.5% neurotoxicity
was reported.
In our study, all 6 patients showing neurotoxicity had
accompanying nephrotoxicity; consistent with that reported
by Sabuda et al. where 4 instances of neurotoxicity (numbness,
muscle weakness and tingling) were reported and all four had
impaired renal function.
Each study has its pros and cons due to the ethical and
practicability issues. In this study the prospective nature of
the study allowed inclusion of cases with a confirmed clinical
infection, eliminating the drawback with retrospective studies.
However, this study was not designed to particularly investi-
gate the effectiveness of colistin, in comparison to a control
group. Due to the small sample size no correlation could be
made with respect to the dosing regimen used and the out-
comes. The use of RIFLE criteria gives a better insight into
the incidence of nephrotoxicity. Despite some of the limita-
tions of the study, we believe the results of the study may be
useful to clinicians and researchers as this is the first study car-
ried out in India on safety and efficacy of colistin.
5. Conclusion
Though the data presented in this study are for a very small
patient pool, they prove that colistin is effective in the treat-
ment of gram negative infections. The occurrence of toxicity
is at an acceptable level. Thus, the benefits outweigh the risk
factors associated with the use of colistin. Colistin should be
used as a reserve drug to treat patients with carbapenem-
resistant gram negative infections. Hence, it is necessary to
monitor the use of colistin such that this resource should be
used judiciously and reserved as the last bastion in thehout nephrotoxicity.
ephrotoxicity Patients without nephrotoxicity
(n= 25)
P-value
57 ± 19.09 0.159
15 ± 10.71 0.411
10 ± 5.01 0.452
18 ± 7.7 0.605
17 (68) 0.481
1 (4) 0.289
3 (12) 1
3 (12) 1
2 (8)
1 (4)
2 (8) 1
8 (32) 0.497
1 (4)
72 K. Desai et al.treatment of serious infections. It is thus imperative to make
the best use of colistin to ensure that it remains as a safe and
effective mode of treatment when need be.
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